Company XYZ reported strong Q2FY24 performance.

Revenue from operations grew 11% year-on-year (YoY) to ₹ 721 Cr, with half-year revenue up 10% to ₹ 1,402 Cr.

EBITDA surged 22% YoY to ₹ 224 Cr, achieving a healthy 31.1% margin.

Profit after tax (PAT) also saw a significant 24% YoY jump to ₹ 185 Cr, boosting EPS by 24% to ₹ 11.02. The company is net cash positive, reporting ₹ (310) Cr net debt.

Growth was broad-based, with Formulations revenue up 11% and APIs up 10%. India Formulations led geographical expansion with 13% YoY growth, alongside strong showings in Emerging Markets (+8%) and Developed Markets (+12%). Strategic focus includes aggressive new product launches, with 8 introduced in India in Q2FY24 and 15-20 more planned for H2FY24, backed by an R&D spend of 4.6% of revenue.

The company also declared a second interim dividend of ₹ 6 per equity share for FY24. Management's outlook emphasizes expanding the India branded business, strengthening the US pipeline, growing in Emerging Markets, and boosting API competitiveness.